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Abstract
Application of gene therapies is a promising approach to the treatment of various neuro‐
logical disorders, including Parkinson's disease, amyotrophic lateral sclerosis (ALS), and
lysosomal storage disorders, which are not treatable by any other means. However, the
blood–brain barrier (BBB) is a key obstacle to gene delivery to the central nervous system
(CNS). Adeno-associated virus (AAV) vectors have emerged as a promising tool for gene
delivery to the CNS, thanks to their safety and ability to transduce non-dividing neuronal
cells. In this chapter, we discuss strategies for delivering genes across the BBB, focusing
especially on potential routes of administration of AAV vectors and promising applica‐
tions of AAV vectors to the treatment of CNS disorders.
Keywords: Adeno-associated virus vector, central nervous system, routes of administra‐
tion, lysosomal storage disorders
1. Introduction
Because it is often difficult to treat central nervous system (CNS) disorders using standard
pharmacological methods, other, more effective, strategies are being sought. Among these
alternatives, gene therapy appears to be a promising approach to treating various neurological
disorders, including Parkinson’s disease, amyotrophic lateral sclerosis, Huntington disease,
Alzheimer’s disease, and lysosomal storage disorders, which are not treatable by any other
methods. However, the efficacy of gene therapies in clinical trials has been limited by phys‐
iological barriers unique to the CNS, as well as by the post-mitotic state of many of the cellular
targets in the brain and spinal cord. The blood–brain barrier (BBB) in particular is a key obstacle
to gene delivery to the CNS.
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Adeno-associated virus (AAV) is a member of the family Parvoviridae that has been widely
used as a vector for gene delivery. AAV is a small, non-enveloped single-stranded DNA virus
with a genome of approximately 4.7 kb [1]. The AAV genome consists of three open reading
frames (ORFs) flanked by two inverted terminal repeats (ITRs). It is a dependovirus because
it requires helper functions from other viruses such as adenovirus or herpes simplex virus for
its replication. AAV is a suitable gene transfer tool because of its safety due to a lack of
pathogenicity, its ability to transduce both dividing and non-dividing cells, and its minor
immune response. Among the more than 100 nonredundant AAV genotypes that have been
identified, 12 AAV serotypes with unique properties have been used to produce most
expression vectors [2].
AAV vectors are powerful tools that are able to mediate gene transfer to the CNS, thanks to
their safety and ability to transduce non-dividing neuronal cells. Consequently, they hold great
potential for use in therapeutic gene delivery strategies for the treatment of neurological
disorders. Although a breakthrough treatment has remained elusive, current approaches are
now considerably safer and potentially much more effective than in the past. In this chapter,
we discuss how to administer vectors across the BBB, focusing especially on potential routes
for administration of AAV vectors and promising strategies for application of AAV vectors in
CNS disorders.
2. AAV vectors for CNS disorders
2.1. Advantages of AAV vectors for gene transfer to CNS
A variety of both viral and non-viral vectors have been applied to the effort to transfer genes
into the CNS. Among these gene transfer methods, AAV vectors have emerged as a particularly
promising tool for gene delivery. There are many advantages to using AAV vectors for
transduction of the CNS [3]. First, AAV is itself not pathogenic and has received a P1 and P1A
recombinant DNA safety classification. It is therefore easy to use AAV vectors without specific
facilities. Second, because AAV vectors have the ability to transduce non-dividing cells, they
are a suitable means for delivering transgenes to non-dividing neuronal cells [4]. Third, long-
term expression of transgenes with little immunogenicity or toxicity can be achieved using
AAV vectors. It was reported that there was a gradual decline in the number of transduced
cells when the cytomegalovirus (CMV) immediate-early promoter was used [5]. However,
with the use of cellular or hybrid promoters, such as the chicken beta-actin/CMV promoter,
transgene expression was sustained. Indeed, we found that following administration to mice
of an AAV vector in which the CAG promoter drove the green fluorescent protein (GFP) gene,
GFP expression was sustained for more than one and a half years, or nearly the entire life span
of the mice [6]. In addition, we are now using several AAV vector serotypes (mainly from AAV
serotype 1 to 12), depending on the target. On the other hand, a disadvantage of AAV vectors
is the size limitation of the transgene. Since AAVs package a ∼4.7-kb genome, it is better to
have 4.7 kb between the inverted terminal repeats at the 5’ and 3’ ends [7].
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2.2. How to cross the BBB?
To apply gene therapy to the treatment of CNS disorders, there are two immediate problems
that must be solved: One is how to cross the BBB, which is a physical and biochemical barrier
that precisely regulates the ability of endogenous and exogenous substances to accumulate
within brain tissue [8, 9], and the second is how to distribute the transgene to the entire brain.
In some cases, we have to treat the whole brain, including the peripheral nervous system (PNS).
To transfer genes across the BBB, there are two main approaches: brain-directed local therapy
and less invasive systemic therapy. Table 1 shows possible approaches of gene delivery to CNS
using AAV vectors.
1. Brain-directed gene transfer
1) Intracranial injection of AAV vector
2. Systemic gene transfer
1) Intravenous injection of AAV vector
2) Intracerebroventricular injection of AAV vector
3) Intrathecal injection of AAV vector
Table 1. Possible approaches of gene delivery to CNS using AAV vectors
3. Local gene delivery to the CNS using AAV vectors
Brain-directed local injection of AAV vectors is a straightforward approach to gene transfer to
the CNS. We compared the transduction efficiency of several AAV vector serotypes encoding
the luciferase gene (AAV/Luc) after intracranial injection in mice. Fig. 1 shows the resultant
transduction efficiencies determined using an in vivo imaging system (IVIS). Efficient trans‐
duction was achieved using the AAV9/Luc or AAV10/Luc vectors compared to the AAV1/Luc
or AAV8/Luc vectors, and sustained expression was detected for at least 6 months after
injection. Notably, however, following injection of a small amount of AAV1/Luc or AAV9/Luc
vectors (2 μl) into the striatum, expression of the transgene was detected in the liver after 2
weeks of injection (Fig. 1A). Therefore, although expression of the transgene was absent at 6
months after injection, one must be aware of the potential for the occurrence of unexpected
transduction following directed local injection of an AAV vector.
Fig. 2 shows another comparison of transduction efficiency after local administration to the
CNS, this time using AAV vectors encoding GFP (AAV/GFP). As expected, the AAV9/GFP
vector exhibited the greatest ability to transduce neuronal cells 2 weeks after injection.
Surprisingly, however, nearly the same high transduction efficiency was detected 2 months
after injection of the AAV2/GFP vector. Although a long time is needed to achieve strong
expression with AAV2, since there is no limitation for the patient, the use of AAV2 is one option
for highly efficient CNS transduction.
Gene Delivery into the Central Nervous System (CNS) Using AAV Vectors
http://dx.doi.org/10.5772/61638
107
Finally, Fig. 3 shows results obtained with direct intracranial injection of AAV1/GFP vectors
into the hippocampus (CA3). Although we injected AAV1/GFP vectors into the right hippo‐
campus (CA3), GFP expression was detected on both sides of the brain, indicating that GFP is
efficiently transported to the left side through long axons. This axonal transport is an advantage
of direct injection [10, 11].
4. Systemic gene delivery to CNS using AAV vectors
Although in some cases axonal transport may be useful for widespread transduction with AAV
vectors, most often local injection of AAV vectors provides transgene expression only to
limited regions in the CNS. Consequently, to obtain global transduction of the CNS, multiple
intracerebral injections are needed. But this strategy is invasive, and safety becomes a problem.
To overcome this problem, an ideal approach for efficient and safe transduction to CNS is
systemic administration.
Figure 1. Brain-directed injection of AAV vectors encoding the luciferase gene (AAV/Luc). (A) Approximately 2.0 x
1010 vector genomes (vg) of recombinant AAV/Luc vectors (serotypes 1, 8, 9, and 10) were injected into the right stria‐
tum over a period of 5 min using a Hamilton syringe with a 33-G blunt-tip needle. Bioluminescent images of mice
were obtained using a Xenogen IVIS imaging system at 2 weeks and 6 months post administration. (B) Comparative
measurement of AAV/Luc transduction in vivo in the brain area 2 weeks and 6 months after injection.
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4.1. Systemic administration of AAV vectors for gene transfer to CNS
4.1.1. Systemic administration of AAV vectors during the neonatal period
Systemic administration of AAV vectors is a promising approach for widespread organ
transduction, though the BBB is an obstacle to the transduction of the CNS. To overcome this
problem, one possibility is to administer the vector during the neonatal period, when the BBB
is immature. We injected AAV/GFP vectors (serotypes 1, 8, 9, and 10: 1.5 x 1011 vg each) into
the jugular veins of neonatal mice and then used diaminobenzidine (DAB) staining to examine
GFP expression. GFP signals were detected throughout the entire brain after injection of any
of these serotypes. Efficient gene transfer was obtained by AAV9/GFP or AAV10/GFP vector
injection (Fig. 4A). Fig. 4B shows immunohistochemical staining of GFP in the brain by
systemic neonatal injection of AAV9/GFP vectors. GFP expression was detected throughout
the brain, including the olfactory bulb, cerebral cortex, hippocampus, and brainstem, and the
spinal cord was also transduced efficiently. However, after the use of the AAV8/GFP vector,
widespread transduction in the brain was detected 2 weeks after injection. Moreover, global
Figure 2. Brain-directed injection of AAV vectors encoding green fluorescent protein gene (AAV/GFP). Approximately
2.0 x 1010 vg of AAV/GFP vectors (serotypes 1, 2, 5, 8, 9, and 10) were injected into the right striatum over a period of 5
min using a Hamilton syringe with a 33-G blunt-tip needle. Expression of GFP was analyzed using fluorescent micro‐
scopy at 2 weeks (A) and 2 months (B) post administration.
Gene Delivery into the Central Nervous System (CNS) Using AAV Vectors
http://dx.doi.org/10.5772/61638
109
expression of GFP was sustained for at least 18 months (Fig. 4C). Immunohistochemical
staining revealed the presence of GFP within GFAP-positive astrocytes, NeuN-positive
neurons, and Calbindin-positive Purkinje cells [6]. These findings suggest that systemic
neonatal administration of AAV is an effective means of delivering transgenes to target
neuronal systems.
4.1.2. Systemic administration of AAV vectors after the neonatal period
It is our experience that AAV vectors are able to pass through the BBB for at least 2 weeks after
birth, but within 6 weeks, all AAV vectors lose the ability to cross the BBB [6]. Therefore, to
transduce the CNS of adult mice, double-stranded (or self-complementary) AAV vectors
(dsAAV) must be used [12]. When we injected single-stranded (ss) AAV9 or dsAAV9 vectors
encoding GFP into the tail veins of 8-week-old mice and assessed GFP expression immuno‐
histochemically, minimal expression was detected in mice administered ssAAV9, whereas
efficient GFP expression was achieved throughout the entire brain using dsAAV9 (Fig. 5).
Thus, systemic administration of the dsAAV9 vector appears to be an effective means of
transducing the CNS in adult mice. It was demonstrated that combined injection of AAV
vectors with mannitol [13, 14] or use of ultrasound-targeted microbubble destruction [15]
enhances gene expression in the brain after systemic injection of AAV vectors. Therefore, to
improve gene delivery in the brain, systemic administration of the dsAAV9 vector, along with
these strategies, may be a powerful tool for transduction to the CNS.
Figure 3. Brain-directed injection of AAV1/GFP vectors into hippocampus (CA3). The CA3 regions of the hippocam‐
pus of 7-month-old mice were injected with AAV1/GFP vectors (8.0 x 109 vg) and examined 5 months later. Using a
fluorescent microscope, slices of the hippocampal regions were analyzed for GFP expression.
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OB, olfactory bulb; CC, cerebral cortex; Hip, hippocampus; PC, Purkinje cells in the cerebellum; BS, brain stem; SC,
spinal cord.
Figure 4. Direct comparison of AAV serotypes to transduce CNS by neonatal systemic injection. (A) After serotype-1,
-8, -9, or -10 AAV/GFP vectors were intravenously injected into neonatal C57BL/6 mice, cerebral GFP expression was
analyzed by DAB staining 4 weeks after injection. Representative brain images showing immunohistochemistry using
an anti-GFP antibody after AAV9/GFP (B) and AAV8/GFP (C) injection.
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Figure 5. Immunohistochemical staining of brain sections of adult mice following systemic injection of ssAAV9/GFP or
dsAAV9/GFP vectors. After 7.0 x 1012 vg of AAV9/GFP vectors were injected via tail veins of adult (7-week-old) mice,
expression of GFP was analyzed using fluorescent microscopy at 5 weeks post administration.
4.2. Intracerebroventricular and intrathecal injection of AAV vectors
Another strategy for achieving global gene transfer into the CNS through systemic adminis‐
tration is vector delivery into the cerebrospinal fluid (CSF). There are two approaches to
delivering an AAV vector into the CSF: intracerebroventricular injection and intrathecal
injection. To evaluate the feasibility of intracerebroventricular injection, AAV1/GFP vectors
were injected into the right lateral ventricle. Following the injection, GFP expression was
broadly distributed in the choroid plexus and ependymal cells throughout the cerebral
ventricles (Fig. 6A). Coronal brain sections revealed widespread diffusion of AAV1 from the
injection site to the contralateral, anterior lateral and third ventricles, as well as the fourth
ventricles via the cerebral aqueduct [16]. GFP expression was mainly confined to the choroid
plexus and ependymal cells, with little or no detection of GFP in the brain parenchyma or
spinal cord. Similarly, when we administered the AAV1/GFP vector intrathecally, GFP
expression was broadly distributed throughout the brain (Fig. 6B). In addition, large numbers
of nerve fibers in the dorsal spinal cord and the neuronal cell bodies in the dorsal root ganglia
were also efficiently transduced [17]. Thus, it can be concluded that both intracerebroventric‐
ular and intrathecal injection of AAV vectors are useful for transduction of the CNS, especially
if one wants to also transduce the peripheral nervous system.
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Figure 6. Expression of GFP in the brain after intracerebroventricular or intrathecal injection of AAV vectors. (A) After
injection of AAV1/GFP vectors into the right lateral ventricle, GFP expression in the brain was analyzed by fluores‐
cence microscopy (upper panel) or immunostaining with DAB staining (lower panel). (B) AAV1/GFP vectors were in‐
jected into the posterior cistern of 8-week-old mice and the brains were examined 8 weeks after injection. GFP
expression was monitored by fluorescence microscopy.
5. Application of AAV vectors to CNS disorders
As summarized above, AAV vectors are an effective means of delivering genes into the CNS,
thanks to their ability to transduce post-mitotic neurons and mediate efficient and stable
transduction. Indeed, the utility of directly delivered AAVs has been demonstrated in
numerous preclinical studies, and they are currently being used in clinical trials of treatments
for Alzheimer’s disease [18, 19], Parkinson’s disease [20, 21], Canavan’s disease [22], and
Batten’s disease [23, 24], among others. We also evaluated the utility of brain directed [25],
intracerebroventricular [16], intrathecal [17], and intravenous neonatal administration [26] of
AAV vectors for the treatment of metachromatic leukodystrophy (MLD), an inherited
lysosomal storage disease with severe neurological symptoms. When we injected AAV9
vectors expressing human arylsulfatase A (AAV9/ASA) into the jugular vein of newborn MLD
model mice, efficient ASA expression was detected throughout the entire brain (Fig. 7A) and
peripheral nervous system (Fig. 7C), suppressing the accumulation of sulfatides in both CNS
(Fig. 7B) and PNS (Fig. 7D). Moreover, the treated mice showed a greater ability to traverse
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narrow balance beams than untreated mice [26]. These data clearly demonstrate that MLD
model mice can be effectively treated through systemic administration of AAV9/ASA vector
to neonates. Thus, neonatal gene therapy is one approach with the potential to overcome the
limitation imposed by the BBB on treating genetic disorders of the CNS. Other advantages of
systemic gene transfer to neonates with genetic disease over treatment of adults are as follows:
(1) because the immune system is immature, recipients are immunologically tolerant of the
vector; (2) it may prevent early onset of genetic diseases; (3) neonates can be effectively treated
with a smaller amount of vectors than adults; and (4) nearly all organs are efficiently trans‐
duced. Systemic neonatal gene therapy thus appears to be a promising method for treating
systemic genetic diseases with neurological symptoms.
Figure 7. Correction of sulfatide storage by neonatal systemic injection of AAV9/ASA vectors. After injection of
AAV9/ASA into the jugular vein of newborn MLD mice, ASA expression in the brain (A) and spinal cord (C) was ana‐
lyzed by immunohistochemistry using an anti-ASA antibody at 15 months after injection. Correction of sulfatide stor‐
age in the brain (B) and spinal cord (D) was analyzed by alcian blue staining.
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6. Summary and future developments
In summary, AAV vectors are a promising tool to transduce both the CNS and the spinal cord.
Following a single systemic injection, AAV vectors cross the BBB and mediate widespread
gene transduction throughout the brain, including the cerebral cortex, cerebellum, olfactory
bulb, and brain stem. Recently, to obtain more efficient transduction, a new AAV vector
serotype [27] or tyrosine mutant capsid [2] was developed. In addition, Rafi et al. succeeded
in treating a mouse model of Krabbe disease (twitcher mice) by administering a combination
of intracerebroventricular, intracerebellar, and intravenous injections of AAV vectors to
neonates [28]. This suggests that administration of AAV vectors via several routes could prove
highly useful for efficient and long-term overexpression or downregulation of genes through‐
out the CNS and spinal cord and could be a useful means of treating genetic neurological
diseases.
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